
|Articles|June 24, 2010
2010 Hema intro
Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan
Advertisement
Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan
Advertisement
Related Content
Advertisement

ByGiuseppe Curigliano,Joyce O'Shaughnessy, MD,François-Clément Bidard,Sung-Bae Kim,Eriko Tokunaga,Philippe Aftimos,Cristina Saura,Lisa A. Carey, MD,Meena Okera,Everton Melo,Flora Zagouri,Manuel Ernesto Magallanes Maciel,Nuri Karadurmus,Shakeela Bahadur,Rebecca M Speck,Xuejing Aimee Wang,Suzanne Young,Komal L. Jhaveri,Nadia Harbeck, MD, PhD

102 Imlunestrant (imlu) With or Without Abemaciclib (abema) in Advanced Breast Cancer (ABC): Safety Analyses From the Phase III EMBER-3 Trial
ByJoyce O’Shaughnessy, MD,Francois Clement Bidard,Patrick Neven, MD, PhD,Monica Lis Casalnuovo,Philippe Aftimos,Cristina Saura,Nadia Harbeck, MD, PhD,Lisa A. Carey, MD,Giuseppe Curigliano,J A Garcia-Saenz,Maria Fernandez Abad,Larissa de Paula,Yeon Hee Park,Ozgur Ozyilkan,Maria Munoz,Sabrina Formentini,Emily Barrett,Shanshan Cao,Aarti Chawla,Komal L. Jhaveri



Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Investigational Radioenhancer Shows Feasibility in Stage III NSCLC
2
Subcutaneous Isatuximab May Optimize Multiple Myeloma Treatment Protocols
3
Mechanistic and Translational Insights of CARv3-TEAM-E in Glioblastoma
4
Fianlimab Combo Does Not Significantly Improve PFS in Advanced Melanoma
5


















































